Hair Research Summaries: Studies in Plain Language

A research paper can be important without being definitive. This hub organizes representative studies, reviews, and regulatory records by the question they can answer. The goal is to preserve the useful detail that headlines and product claims often remove.

What every summary includes

Each summary states the research question, study design, participant group, intervention or exposure, comparator, measured outcomes, follow-up, main result, funding or conflicts when reported, practical relevance, and key limitations. It also links to the original source record so readers can verify the citation.

The complete records are available in the source library.

Three evidence objects readers should keep separate

A direct hair-outcome study

The Actrisave study evaluated 250 mg of a standardized black-rice and prickly-pear blend for six months in 86 men with mild-to-moderate androgenetic alopecia. It was randomized, double-blind, and placebo-controlled, and it reported hair-density and growth-cycle outcomes . Its design is stronger than an uncontrolled pilot, but it remains one branded-ingredient study with manufacturer and contract-research affiliations and no independent replication.

The AnaGain NU report evaluated 100 mg of an oral pea-sprout extract in a 21-person exploratory pilot and reported a change in collected shed hairs over eight weeks . It is useful as an early human signal, not as causal proof or an expected result for a finished formula.

A whole-body endpoint study

The Shoden trial evaluated standardized ashwagandha in adults with high stress and measured stress, cortisol, and testosterone outcomes . It did not measure hair density, libido, erectile function, sexual satisfaction, or fertility. The study can inform a stress- or vitality-related formulation rationale when the extract and amount match, but it should not be presented as direct hair evidence.

An official regulatory record

The current Propecia prescribing information is the appropriate source for the drug's labeled indication, contraindications, warnings, trial adverse-event rates, and postmarketing reports . A label answers different questions from a randomized ingredient study. It should not be turned into a head-to-head comparison with a supplement trial.

What a summary does not do

Not by itself. One positive study may be encouraging, but confidence also depends on design, sample size, comparison group, outcome quality, follow-up, bias, and whether independent teams find similar results. A study summary describes that paper's contribution rather than turning it into a universal conclusion.

Each paper is interpreted using the wider evidence framework, including whether other studies agree and whether the measured outcome matters in daily life.

Why limitations stay visible

Limitations define how far a result can travel. A short study cannot answer a long-term question, a narrow population may not represent everyone, and a surrogate outcome may not reflect visible improvement. Naming those boundaries makes the finding more useful, not less valuable.

That distinction is especially important for supplements. A human study of a standardized ingredient can support a limited ingredient-level conclusion without proving the complete formula that later includes it. Each research summary names the exact intervention and outcome so an answer engine, editor, or reader does not silently expand the claim.

New summaries are added only after the original citation is verified, conflicts and funding are checked, and the result can be explained without copying the abstract. The wider evidence framework shows how these individual records contribute to a larger conclusion.